RAF1 and cancer: Since the Raf–MAPK cascade exerts its regulatory function downstream of cell surface receptors and dysregulated in cancer and other human pathologic disorders [54, 55], revealing this canonical signaling network could develop as pharmacologic inhibitors to block Raf–MAPK signaling for the treatment of chronic joint disease.